ClinicalTrials.gov
public full text
Public Domain
Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection. The total study duration is up to 28 days.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Long-term Pulmonary Outcomes After Infection With Sars-CoV-2#912550
- Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case–Control Study.#317955
- Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine#867881
- Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)#481788
- Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers#432935
Record · ID 1060666
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive